The SENTRY Study: Early Ovarian Cancer Diagnosis
The SENTRY Study is looking at a new way to diagnose ovarian cancer early. Researchers are testing if changes in platelet RNA expression (genetic material in blood cells called platelets) combined with a special analysis can accurately find ovarian cancer. This study is for women aged 21 or older who have recently been diagnosed with an ovarian or pelvic mass. The main goal is to see how well this method can detect early-stage ovarian cancer. The study is currently recruiting participants to validate findings from previous research.
- Study design
- This is an observational study planning to enroll 245 women. It is designed to test a diagnostic method rather than a treatment.
- What's involved
- You would provide a blood sample for platelet RNA analysis after giving informed consent. This would occur at study visit 1, day 1.
- Compensation
- Not stated in the trial record.
- Follow-up
- Early-stage ovarian cancer detection is measured at the time of informed consent (study visit 1, day 1).
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Theresa Werner, MD · PRINCIPAL_INVESTIGATOR · Huntsman Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Early-Stage Ovarian Cancer DetectionFollowing informed consent (study visit 1, day 1).
The goal is to determine if changes in platelet RNA expression accurately diagnoses ovarian cancer. This outcome will report the number of true positive, true negative, false positive, and false negative results from this assay.